The CCL2-CCR2 axis contributes to acquired osimertinib resistance in lung cancer by upregulating Zeb1 expression
Tzu-Hua Chang,
Meng-Feng Tsai,
Shang-Gin Wu
et al.
Abstract:Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), effectively treats non-small-cell lung cancer patients with EGFR activation mutations or those with acquired T790M resistance mutation following EGFR-TKIs therapy. However, the development of drug resistance remains a significant clinical challenge. Therefore, we aimed to investigate novel cytokine signaling pathways contributing to osimertinib resistance in lung cancer. Our findings revealed that the CCL2… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.